Inactive Instrument

EQRx, Inc.

Equities

EQRX

US26886C1071

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Revolution Medicines Closes Acquisition of EQRx in All-Stock Deal MT
EQRx, Inc. Announces Board Resignations CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from NASDAQ Composite Index CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P Global BMI Index CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P Biotechnology Select Industry Index CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P TMI Index CI
Revolution Medicines, Inc. completed the acquisition of EQRx, Inc. from a group of shareholders. CI
Revolution Medicines, EQRx Stockholders Approve Merger MT
EQRx, Inc.(NasdaqGM:EQRX) dropped from NASDAQ Biotechnology Index CI
EQRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
EQRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Hansoh Pharmaceutical Terminates License Agreement With EQRx for Aumolertinib; Shares Slump 10% MT
EQRx, Inc. Provides Written Notice to G1 Therapeutics of its Termination of the Exclusive License Agreement CI
EQRx, Inc. Provides Written Notice to Hansoh Healthtech Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Company Ltd. of Its Termination of the Strategic Collaboration License Agreement CI
Revolution Medicines Shares Rise After Accord to Acquire EQRx in All-Stock Deal MT
Sector Update: Health Care Stocks Decline Premarket Tuesday MT
Sector Update: Health Care MT
Revolution Medicines Agrees to Acquire EQRx in All-Stock Deal MT
Transcript : EQRx, Inc., Revolution Medicines, Inc. - M&A Call
Revolution Medicines Agrees to Acquire EQRx in All-Stock Deal MT
Revolution Medicines, Inc. entered into a definitive agreement to acquire EQRx, Inc. from a group of shareholders for approximately $930 million. CI
Goldman Sachs Lowers EQRx's Price Target to $3 From $5, Neutral Rating Kept MT
CStone Pharmaceuticals to Regain Commercialization Rights to Cancer Treatments MT
EQRx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : EQRx, Inc., Q1 2023 Earnings Call, May 08, 2023
Chart EQRx, Inc.
More charts
EQRx, Inc. is a pharmaceutical company. The Company is engaged in developing medicines for some of the prevalent disease areas, including cancer and immune-inflammatory conditions. The Company brands include EQRx and Remaking Medicine. The Company's pipeline is comprised of approximately 10 programs, including both small molecules and biologics, with five clinical-stage programs, and several disclosed and undisclosed preclinical and drug engineering programs. Its clinical programs include Aumolertinib (EQ143), Lerociclib (EQ132), and Sugemalimab (EQ165). Aumolertinib (EQ143) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lerociclib (EQ132) is a novel and oral small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor. Sugemalimab (EQ165, also known as CS1001) is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody.
More about the company
  1. Stock
  2. Equities
  3. Stock EQRx, Inc. - Nasdaq
  4. News EQRx, Inc.
  5. Sector Update: Health Care Stocks on Downward Slide